AUGUST 2, 2021
Top line results of SARA-INT Phase 2 study with Sarconeos (BIO101) in Sarcopenia
JULY 19, 2021
Judgment rendered on July 16, 2021 in the proceedings between Biophytis and Negma Group Ltd by the Execution Judge from the Paris Court of Justice
JULY 12, 2021
Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021
April 19, 2021
Interview of Stanislas Veillet, CEO of Biophytis on La Bourse ou la Vide.com (in French)
FEBRUARY 26, 2021
Biophytis Reports 2020 Full Year Results
FEBRUARY 17, 2021
Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) following Regulatory Authorities approvals in France and Belgium
February 15, 2021
Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market
February 10, 2021
Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market
FEBRUARY 10, 2021
Biophytis Announces Temporary Trading Halt of its Shares and Share Warrants on Euronext Growth
February 3, 2021
Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”)